Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
State-of-the Art on Cervical Cancer
share announcement

State-of-the Art on Cervical Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: closed (15 July 2023) | Viewed by 5129

Special Issue Editors

Dr. Alessandro Antonio Buda

E-Mail Website
Guest Editor
Division of Gynecologic Oncology, Michele e Pietro Ferrero Hospital, Verduno, Italy
Interests: oncological surgery and pelvic surgery; mininvasive laparoscopic surgery
Dr. Francesco Fanfani

E-Mail Website
Guest Editor
Department of Life Sciences and Public Health, Gemelli Polyclinic Hospital, Rome, Italy
Interests: gynecologic oncology; ovarian cancer; cervical cancer; endometrial cancer; minimally invasive surgery; laparoscopy

Special Issue Information

Dear Colleagues,

Treatment of cervical cancer still represents a challenge particularly when it is diagnosed in the locally advanced stage. It is the fourth most common cancer among women. In recent decades many advanced were carried on prevention by vaccination of HPV and screening of pre-invasive disease. However, all preventive strategies will be effective only in the distant future, 20 to 30 years from now.

In this Special Issue, an international team of experts will try to discuss and address a comprehensive scenario on the state-of-the-art of this disease. Topics ranging from a epidemiology and demography of cervical cancer, to clinical reviews and original papers on diagnosis and prevention programs, the role of surgery, particularly regarding the sentinel node mapping and lymphadenectomy, modulation of radical hysterectomy, the fertility sparing approaches, the role of radiotherapy and combined modality treatment are all welcome.

Dr. Alessandro Antonio Buda
Dr. Francesco Fanfani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • surgery
  • sentinel node mapping
  • diagnosis, prevention, treatment
  • radiotherapy
  • chemotherapy
  • fertility sparing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 580 KiB  
Article
Role of Adjuvant Radiotherapy in Patients with Cervical Cancer Undergoing Radical Hysterectomy
by María Alonso-Espías, Mikel Gorostidi, Myriam Gracia, Virginia García-Pineda, María Dolores Diestro, Jaime Siegrist, Alicia Hernández and Ignacio Zapardiel
J. Pers. Med. 2023, 13(10), 1486; https://doi.org/10.3390/jpm13101486 - 12 Oct 2023
Cited by 1 | Viewed by 1416
Abstract
The benefit of adjuvant radiotherapy (RT) after radical hysterectomy in patients with cervical cancer remains controversial. The aim of this study was to determine adjuvant RT’s impact on survival in accordance with Sedlis criteria. Patients with early-stage cervical cancer undergoing radical hysterectomy between [...] Read more.
The benefit of adjuvant radiotherapy (RT) after radical hysterectomy in patients with cervical cancer remains controversial. The aim of this study was to determine adjuvant RT’s impact on survival in accordance with Sedlis criteria. Patients with early-stage cervical cancer undergoing radical hysterectomy between 2005 and 2022 at a single tertiary care institution were included. A multivariate analysis was performed to determinate if RT was an independent prognostic factor for recurrence or death. We also analysed whether there was a statistically significant difference in overall survival (OS) between patients who met only one or two Sedlis criteria, depending on whether they received adjuvant RT or not. 121 patients were included in this retrospective study, of whom 48 (39.7%) received adjuvant RT due to the presence of unfavourable pathological findings. In multivariate analysis, RT was not found to be a statistically significant prognostic factor for OS (p = 0.584) or disease-free survival (DFS) (p = 0.559). When comparing patients who met one or two Sedlis criteria, there were no statistically significant differences in OS between RT and no adjuvant treatment in either group. Since the selection of patients with cervical cancer eligible for surgery is becoming more accurate, adjuvant RT might not be necessary for patients with intermediate risk factors. Full article
(This article belongs to the Special Issue State-of-the Art on Cervical Cancer)
►▼ Show Figures

Figure 1

11 pages, 451 KiB  
Article
Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer
by Thomas Bartl, Christoph Grimm, Robert M. Mader, Christoph Zielinski, Gerald Prager, Matthias Unseld and Merima Herac-Kornauth
J. Pers. Med. 2023, 13(8), 1186; https://doi.org/10.3390/jpm13081186 - 26 Jul 2023
Cited by 2 | Viewed by 1289
Abstract
(1) Objective: Late-line chemotherapy rechallenge in recurrent cervical cancer is associated with modest therapy response but significant side effects. As mTOR pathways modulate cellular growth via estrogen receptor (ER) signaling and combined mTOR and ER inhibition previously demonstrated survival benefits in breast cancer, [...] Read more.
(1) Objective: Late-line chemotherapy rechallenge in recurrent cervical cancer is associated with modest therapy response but significant side effects. As mTOR pathways modulate cellular growth via estrogen receptor (ER) signaling and combined mTOR and ER inhibition previously demonstrated survival benefits in breast cancer, this exploratory study evaluates mTOR pathway and ER expression interactions in a preclinical cervical cancer model. (2) Methods: Immunostaining of a 126-tumor core tissue microarray was performed to assess phosphorylated-mTOR and ER expression. To identify tumor subsets with different clinical behavior, expression results were matched with clinicopathologic patient characteristics, and both univariate and multivariable survival statistics were performed. (3) Results: phosphorylated-mTOR correlates with ER (r = 0.309, p < 0.001) and loss of PTEN expression (r = −2.09, p = 0.022) in tumor samples across stages but not in matched negative controls. Positive ER expression is observed significantly more often in phosphorylated-mTOR positive samples (30.0% vs. 6.3%, p = 0.001). In the subgroup of phosphorylated-mTOR positive tumors (n = 60), ER expression is associated with improved survival (p = 0.040). (4) Conclusion: ER expression appears closely intertwined with EGFR/PTEN/mTOR-pathway activation and seems to define a subgroup with clinically distinct behavior. Considering limited therapeutic options in recurrent cervical cancer, further validation of combined mTOR and ER inhibition in selected patients could appear promising. Full article
(This article belongs to the Special Issue State-of-the Art on Cervical Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 520 KiB  
Review
Radical Hysterectomy in Early-Stage Cervical Cancer: Abandoning the One-Fits-All Concept
by Tommaso Bianchi, Tommaso Grassi, Luca Bazzurini, Giampaolo Di Martino, Serena Negri, Robert Fruscio, Gaetano Trezzi and Fabio Landoni
J. Pers. Med. 2023, 13(9), 1292; https://doi.org/10.3390/jpm13091292 - 24 Aug 2023
Cited by 3 | Viewed by 2090
Abstract
Two pillars in modern oncology are treatment personalization and the reduction in treatment-related morbidity. For decades, the one-fits-all concept of radical hysterectomy has been the cornerstone of early-stage cervical cancer surgical treatment. However, no agreement exists about the prevalent method of parametrial invasion, [...] Read more.
Two pillars in modern oncology are treatment personalization and the reduction in treatment-related morbidity. For decades, the one-fits-all concept of radical hysterectomy has been the cornerstone of early-stage cervical cancer surgical treatment. However, no agreement exists about the prevalent method of parametrial invasion, and the literature is conflicting regarding the extent of parametrectomy needed to achieve adequate surgical radicality. Therefore, authors started investigating if less radical surgery was feasible and oncologically safe in these patients. Two historical randomized controlled trials (RCTs) compared classical radical hysterectomy (RH) to modified RH and simple hysterectomy. Less radical surgery showed a drastic reduction in morbidity without jeopardizing oncological outcomes. However, given the high frequency of adjuvant radiotherapy, the real impact of reduced radicality could not be estimated. Subsequently, several retrospective studies investigated the chance of tailoring parametrectomy according to the tumor’s characteristics. Parametrial involvement was shown to be negligible in early-stage low-risk cervical cancer. An observational prospective study and a phase II exploratory RCT have recently confirmed the feasibility and safety of simple hysterectomy in this subgroup of patients. The preliminary results of a large prospective RCT comparing simple vs. radical surgery for early-stage low-risk cervical cancer show strong probability of giving a final answer on this topic. Full article
(This article belongs to the Special Issue State-of-the Art on Cervical Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop